Anti-Inflammatory Therapy for Acute Coronary Syndromes: Is It Time for a Shift in the Treatment Paradigm?
- PMID: 35856903
- DOI: 10.1097/FJC.0000000000001338
Anti-Inflammatory Therapy for Acute Coronary Syndromes: Is It Time for a Shift in the Treatment Paradigm?
Conflict of interest statement
G. Biondi-Zoccai has consulted for Cardionovum, Crannmedical, Innovheart, Guidotti, Meditrial, Opsens Medical, Replycare, Teleflex, and Terumo. The remaining authors report no conflicts of interest.
Comment on
-
Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 - a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein-like Receptor 1- on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction.J Cardiovasc Pharmacol. 2022 Nov 1;80(5):672-678. doi: 10.1097/FJC.0000000000001331. J Cardiovasc Pharmacol. 2022. PMID: 35881895
References
-
- Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling . Nat Rev Cardiol. 2014. 11:255–265.
-
- Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges . Br J Pharmacol. 2018. 175:1377–1400.
-
- Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology . Eur Heart J. 2016. 37:1015–1023.
-
- Arslan F, Smeets MB, O'Neill LA, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody . Circulation. 2010. 121:80–90.
-
- Toldo S, Austin D, Mauro AG, et al. Low-density lipoprotein receptor-related protein-1 is a therapeutic target in acute myocardial infarction . JACC Basic Transl Sci. 2017. 2:561–574.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
